Aims: PRRT2 was recently identified as a causative gene for paroxysmal kinesigenic dyskinesia (PKD), and the c.649dupC mutation was shown to be a "high frequency" mutation. This mutation was also identified in many sporadic cases. This might be attributed to the incomplete penetrance of c.649dupC. Alternatively, c.649dupC might derive from de novo. The aim of this study is to elucidate the possibility concerning de novo mutagenesis of PRRT2 mutations in PKD. Methods: Nine sporadic Chinese PKD patients including one Mongolian patient were recruited. Direct sequencing of PRRT2 was performed in them and their parents. Haplotype analysis was conducted to confirm the biological relationship. Results: A novel mutation, c.133_136delCCAG, was identified in one Han patient and his unaffected mother. The c.649dupC mutation was detected in another Han patient and his unaffected father. To our interest, c.649dupC was detected in the Mongolian patient but not in his parents. Haplotype analysis confirmed the biological relationship among the trio. No mutations were identified in the remaining six patients. Conclusion: These findings demonstrate the heterogeneity of PKD, and the de novo mutagenesis of PRRT2 gene might indicate the genetic instability of this region.
Introduction
Paroxysmal kinesigenic dyskinesia (PKD) is an autosomal dominant movement disorder with incomplete penetrance and characteristics of involuntary attacks precipitated by sudden movements [1] . Attacks consist of choreoathetosis, dystonia or ballism with a brief duration and a frequency ranging from one per month to 100 per day [2, 3] . Despite being a hereditary disorder, PKD is both clinically and genetically heterogeneous. It can co-occur with other episodic disorders, such as benign familial infantile epilepsy or infantile convulsions [4, 5] . In clinical practice, PKD is often misdiagnosed as epilepsy because of its episodic, paroxysmal features and favorable response to antiepileptic drugs (AEDs), among which carbamazepine and phenytoin are widely considered as drugs of choice.
Recently, PRRT2-encoding proline-rich transmembrane protein 2 was identified as a causative gene for PKD by several independent groups [6] [7] [8] . Our previous study showed that c.649dupC mutation was identified in six of eight Chinese Han families, accounting for a percentage as high as 75% [6] . The high frequencies of c.649dupC mutation were also observed in two independent studies in China [7, 8] . Moreover, the majority of reported patients affected by PKD with infantile convulsions (PKD/IC), infantile convulsions with choreoathetosis syndrome, or benign familial infantile convulsions were also detected to harbor c.649dupC mutation [9] [10] [11] [12] . These together implied that c.649dupC mutation is a probable mutation "hot spot" within PRRT2. However, the potential molecular mechanism of c.649dupC mutagenesis remains unclear.
In addition, the high frequencies of c.649dupC mutation were also identified in sporadic PKD cases. This phenomenon might be attributed to the incomplete penetrance of c.649dupC mutation. Alternatively, c.649dupC mutation might derive from de novo mutagenesis in sporadic cases. To test this hypothesis, we screened PRRT2 mutations in nine patients with sporadic PKD and their parents. In one family with Mongolian background, we detected c.649dupC mutation in the proband, but failed to detect it in his parents. Haplotype analysis confirmed the biological relationship among the trio, indicating the de novo origin of c.649dupC mutation in this case. To the best of our knowledge, this is the first report concerning de novo mutagenesis of PRRT2 mutations in Chinese PKD.
Patients and Methods

Patients
The protocols of this study were approved by the ethics committees of Huashan Hospital, Fudan University. Nine patients with sporadic PKD who met Bruno criteria [1] and their parents were recruited in Neurology Clinic of Huashan Hospital between April 20 and August 6, 2012. One patient was of Mongolian descent and the other eight were Chinese Han. They are from Jiangsu (four patients), Zhejiang (two patients), Jiangxi (two patients), and Inner Mongolia (one patient).
Screening of PRRT2 Mutations
Peripheral blood was collected after obtaining informed consents from all the patients and their parents. Genomic DNA was extracted using a Blood Genomic DNA Extraction kit (Tiangen, Beijing, China). To analyze PRRT2, fragments encompassing each of the four coding exons and corresponding splice junctions were amplified by polymerase chain reaction (PCR). Sequences of forward and reverse PCR primers and the annealing temperatures have been previously described [6] . PCRs were carried out in a final volume of 20 lL, containing 40 ng of genomic DNA and 12.5 pmol of both forward and reverse primers. Amplified products were purified, and DNA direct sequencing was performed using an ABI 3730 Automated DNA Sequencer (Applied Biosystems, Foster City, CA, USA). The resulting sequences were aligned to the NCBI human reference DNA sequence of PRRT2 (Ensembl gene identification number ENSG00000167371), and nucleotide changes were numbered corresponding to their position within the PRRT2 mRNA (NCBI Reference Sequence: NM_145239.2).
Haplotype Analysis
To address the possibility that the family members were genetically related, we performed haplotype analysis based on 18 single nucleotide polymorphisms (SNPs). Among these SNPs, rs1045968 and rs10204 were located within PRRT2, while others (rs3953219, rs2071420, rs9922666, rs7205278, rs235649, rs9923649, rs1057451, rs1057452, rs9938630, rs4788186, rs13332660, rs3844222, rs9926856, rs1129700, rs9928448, and rs4788172) flanked PRRT2. All 18 SNPs were genotyped using Sequenom MassARRAY system at Fudan-Van Andel Research Institute (VARI) Center (School of Life Science, Fudan University, China). We used Mass-ARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA) to design the PCR primers used in the genotyping. Sequences of the forward and reverse PCR primers for these 18 SNPs were shown in Table 1 . The resulting products were desalted and transferred to a 384-element SpectroCHIP array (Sequenom). Allele was detected using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The probability of the patient being biological son of the alleged parents was calculated by reverse parentage testing, as previously reported [13] . Paternity Index (PI) was calculated for each genetic locus and then multiplied together to obtain a combined paternity index (CPI) for all the genetic loci examined. By definition, we had CPI = p/(1Àp) with p representing the probability of the child being the biological son of the alleged parents. P is then calculated as CPI/(1 + CPI).
Results
Identification of PRRT2 Mutations
After conducting sequencing of PRRT2 gene in nine sporadic patients, two patients (case 4 and 7) were detected to carry the most common PRRT2 mutation, c.649dupC, and one (case 8) carry 
A/G ACGTTGGATGTGGAAGGGCAGAAGCAACG ACGTTGGATGCACTCAGGGTAGAAGCCAAG CTGACCCCTGCCTACCTCT SNPs, single nucleotide polymorphisms.
a novel mutation, c.133_136delCCAG (Figure 1 ). The novel mutation causes a deletion of Pro 44 and a frameshift within the codon for Glu 45 , resulting in the substitution of arginine for proline and the addition of 43 additional novel amino acid residues prior to the termination at a stop codon within the new reading frame (p.Pro45Argfs*44). No nucleotide changes were identified in the other six patients. Furthermore, we screened PRRT2 mutations in the parents of three patients (case 4, 7, and 8) carrying PRRT2 mutations. We also detected the c.649dupC mutation in the unaffected father of case 7 and the c.133_136delCCAG mutation in the unaffected mother of case 8, indicating an incomplete penetrance. However, in the case 4 with Mongolian background, we failed to identify any variants within PRRT2 in both his father and his mother. This implies that the mutation in this patient may derive from de novo. Thus, we had to confirm the biological relationship among them.
Haplotype Analysis
As shown in Figure 2 , the patient with Mongolian background inherited one haplotype from his mother and another one from his father. Using reverse parentage testing, we obtained a CPI 1378.25 in this family. The P value was therefore calculated as 0.9993, reflecting a 99.93% probability that the patient was the biological son of the alleged parents. This confirmed the biological relationship among the trio and further indicated that the c.649dupC mutation in this patient did derive from de novo mutagenesis.
Clinical Presentations
Among nine sporadic patients, two are women and the other seven are men. Age at onset ranged from 3 to 18 years. Electroencephalogram (EEG) and brain magnetic resonance imaging (MRI) revealed normal results in all of them. The clinical features of these nine sporadic PKD cases were summarized in Table 2 .
The clinical manifestations of the case 4 were described in detail as follows because of his de novo mutagenesis. The prenatal history of this case was negative and his developmental milestones were normal. He had no significant medical history. The attacks were first evident at the age of 12 when the patient stood up quickly to answer teacher's question in class. His head turned to one side with his face twisted, his arms extended at the elbow and abducted at the shoulder, and his hands flexed at the wrist. He then began ballistic flailing, followed by athetotic movements of the torso. The attacks lasted about 20 seconds, making all of his classmates as well as his teacher stunned by his abnormal behaviors. He was fully aware of his surrounding during the attacks, which made him very embarrassed. He then sought his medical care in local hospital and was diagnosed with epilepsy, although his general physical and neurological examinations disclosed unremarkable findings and brain MRI, 24-h video-EEG revealed normal results. Valproate and clonazepam were prescribed to treat his attacks but showed null effect. In the following months, he developed similar dyskinesias triggered by a variety of sudden movements such as standing up, running, or jumping. The events usually lasted from 10 to 30 seconds and occurred up 3-5 times daily at the beginning and increased to 5-10 times per day at the age of 13-15. Stress and anxiety seemed to lower the threshold for attacks, heightening the likelihood and frequency of spells. He was misdiagnosed with epilepsy in the following 9 years and was prescribed various AEDs such as valproate, phenobarbital, gabapentin, phenytoin, and clonazepam. He took these AEDs irregularly and his dyskinesia was not completely controlled. Symptoms were significantly relieved, but the attacks still occurred intermittently. Day after day, he learned to act slowly to prevent the attacks when he felt the episodes were occurring.
Five months ago, he came to our hospital for further treatment. A diagnosis of PKD was made and he was prescribed carbamazepine at a low dosage of 50 mg once daily. A complete resolution of signs was achieved 2 days after initiation of carbamazepine. No side effects were reported. But even so, the carbamazepine was still necessary for him, because discontinuation of carbamazepine for 3 days resulted in a return of the attacks.
Discussion
Paroxysmal kinesigenic dyskinesia represents a group of episodic movement disorders that are usually triggered by sudden movements. Since the first description by Kertesz in 1967 [14] , immense effort has been made to detect the causative locus for PKD. No susceptibility gene, however, was detected until recently, when several independent groups showed that mutations in PRRT2 were causative for PKD [6] [7] [8] . By now, more than 20 PRRT2 mutations have been identified in patients affected with PKD or PKD/IC [6] [7] [8] [9] [10] [11] [12] , and c.649dupC mutation accounted for a percentage approximate 80% [11] . However, the molecular mechanisms of c.649dupC mutation await to be elucidated.
In the current study, we collected nine sporadic PKD cases and identified the c.649dupC mutation in two cases and a novel c.133-136delCCAG mutation in one case. We further confirmed that the c.649dupC mutation derived from de novo in the case with Mongolian background. This finding implies that the site between bases 649 and 659 is unstable. We conjecture that the mutagenesis of c.649dupC is a consequence of the nature of the DNA sequences adjacent to cytosine 649 , where it is one of nine consecutive cytosine (C) bases. It is likely that this run of C-residues facilitates "slippage" of DNA polymerase, leading to an insertion of a C base during DNA replication. Therefore, insertion of a C base in any position among the nine C bases would result in a frameshift mutation at this locus. Why cytosine 649 is particularly susceptible to duplication, however, remains to be explained. Although the PKD causative gene has been cloned, the pathophysiology and the function of PRRT2 protein remain to be elucidated. PRRT2 is a proline-rich transmembrane protein, containing two predicted transmembrane domains within its C terminus. Expression has been detected primarily in the central nervous system, especially in developing brain [6] . More importantly, a yeast two-hybrid study suggests that PRRT2 interacts with the synaptosomal-associated protein 25 kDa (SNAP25) [15] , which plays a crucial role in calcium-triggered neurotransmitter release from synaptic vesicles [16] . There is a possibility that PRRT2 regulates ion channels during vesicular release [10, 17] , although this has yet to be experimentally confirmed. As most reported PRRT2 mutations are truncating mutations, we speculate that truncated PRRT2 proteins cannot anchor to the membrane and therefore loses its ability to interact with SNAP25, thus disturbing synaptic functions. Additional studies will be required to elucidate the properties of the PRRT2 protein as well as its functions.
In summary, we present a de novo origin of the c.649dupC mutation and a novel c.133_136delCCAG mutation in this study. To the best of our knowledge, this is the first report concerning de novo mutagenesis of c.649dupC in Chinese PKD, which might generate much benefit to understand the molecular mechanism of PKD.
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